Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
65.5M
-
Shares change
-
+1.7M
-
Total reported value, excl. options
-
$2.03B
-
Value change
-
+$61.5M
-
Put/Call ratio
-
0.83
-
Number of buys
-
83
-
Number of sells
-
-63
-
Price
-
$31.04
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q4 2021
192 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 65.5M shares
of 89.4M outstanding shares and own 73.23% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (5.61M shares), BlackRock Inc. (4.52M shares), ARMISTICE CAPITAL, LLC (4.08M shares), JANUS HENDERSON GROUP PLC (4.02M shares), VANGUARD GROUP INC (3.88M shares), MACQUARIE GROUP LTD (3.77M shares), STATE STREET CORP (2.89M shares), BAKER BROS. ADVISORS LP (2.67M shares), GOLDMAN SACHS GROUP INC (2.59M shares), and Deep Track Capital, LP (2.45M shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.